Providing Care to a Hematopoietic CELL Transplant Recipient: Caregivers Describe Their Own Quality of Life  by Jim, Heather et al.
p
KPS <0.0001
Walk velocity <0.0001
PBSC 0.0077
Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150S148Methods: The present study examined the association
between fatigue, pain, overall quality of life, and perceived
health status with employment at 1-year post-transplant.
Participants (N¼404) completed a lifestyle survey 1-year
post-SCT. Participants provided current employment sta-
tus and whether change was attributable to their health
status.
Results: Participants were predominatelymarried/partnered
(81.7%), Caucasian/Non-Hispanic (81.6%), males (52%) be-
tween ages 19-76 (mean: 56 years) and majority underwent
autologous transplants (70.1%). Prior to illness diagnosis,
60.8% were employed Full-Time, which decreased at the time
of transplant (35.5%) and at 1-year post-SCT (31.0%).
Employment status was correlated with all variables of in-
terest (p<0.05). Analysis of variance and chi-square analysis
were completed. Fatigue, pain, and quality of life were rated
on a 0-10 scale. Health status was rated as ‘excellent’ to ‘poor’
on a 5-point scale. Patients’ mean scores revealed low/
moderate fatigue (3.38), low pain (1.87) and good quality of
life (7.43). Most rated their health as ‘very good’ (26.9%) or
‘good’ (22.7%). Fatigue did not vary by employment status.
Pain was greatest for patients unemployed due to health
status compared to those employed full-time or unemployed
due to other (p<.05). Patients employed part-time enjoyed
greater quality of life than those unemployed due to Health
status (p<.05). Those employed full-time were most likely to
report ‘excellent’ (48.0%), ‘very good’ (37.5%), or ‘good’
(33.9%) health. ‘Fair’ health was mostly reported by those
unemployed due to health status (41.3%). Retirees, regardless
of health status, were most likely to report ‘poor’ health
(57.2%).
Conclusion: Patients’ ability and desire to return to work
post-transplant should be considered a meaningful compo-
nent of survivorship expectations and long-term adjustment.206
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Univariate analysis
Not fatigued
(N¼160)
Fatigued
(N¼103)
p
# prior cGVHD
therapies
3.5 4.2 0.007
PCS 39.3 29.9 <0.0001
MCS 50.4 42.4 <0.0001
ESR 22.6 28.8 0.007
CRP 6.1 7.7 0.019
TSH 1.8 2.2 0.035
HAP max activity score 74.7 65.4 <0.0001
HAP adj activity score 64.8 50.0 <0.0001
Nutrition score PG-
SGA
6.0 9.6 <0.0001Institute, NIH, Bethesda, MD; 5 Pain and Palliative Care,
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Background: Chronic graft-versus-host disease (cGVHD) is a
major cause of morbidity and non-relapse mortality after
allogeneic hematopoietic cell transplantation (HCT).
Although fatigue is common after HCT, little is known about
fatigue in patients with cGVHD. The aim of this study was to
explore factors associated with fatigue in cGVHD.
Methods: Data were drawn from a cohort of adults with
cGVHD (n¼263). To classify patients as fatigued, a single item
(extent to which respondent was bothered in the past month
by loss of energy [LOE]) from the Lee cGVHD Symptom Scale
was employed. Those who were ‘not at all’, ‘slightly’, or
‘moderately’ bothered by LOE were classiﬁed as not fatigued;
those who were ‘quite a bit’ or ‘extremely’ bothered were
classiﬁed as fatigued. Nonparametric tests were used to
compare variables of interest in patients with and without
fatigue; logistic regression was used to model predictors of
fatigue.
Results: In univariate analysis, several parameters were
signiﬁcantly associated (p<0.005) or demonstrated a trend
towards signiﬁcant association (0.005p<0.05) with fatigue
(Table 1). Factors not associated were NIH global severity
score, NIH organ scores, # of involved organs, time since
cGVHD onset, platelets, hemoglobin, albumin, erythematous
or sclerotic skin involvement, intensity of immunosuppres-
sion, therapeutic intent at time of evaluation, age, gender,
BMI, conditioning regimen, donor source, C3, C4, pre-
albumin, ferritin, lung function score, FEV1, respiratory
symptoms, range of motion, and grip strength. Logistic
regression modeling initially including factors associated
with fatigue in univariate analysis demonstrated that having
received peripheral blood stem cells (PBSC) and having im-
pairments in self-rated physical and mental health predicted
fatigue. Fatigued respondents had SF36 physical component
score (PCS) and mental component score (MCS) means that
were markedly lower than US normative value, and human
activity proﬁle (HAP) scores reﬂecting limitation in daily
activities.
Conclusions: The absence of association with either NIH
cGVHD global severity or organ scores suggests that fatigue
in cGVHD patients may have a distinct pathogenesis. The
association with ESR and CRP point towards possible in-
ﬂammatory mediators. Findings conﬁrm the deleterious
impact of fatigue on self-rated health and daily activities, and
emphasize the need for routine screening in HCT survivors.
Further study of the characteristics, correlates, and conse-
quences of fatigue in cGVHD is warranted.207
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Background: Although a great deal of research has focused
on patient quality of life (QOL) after hematopoietic cell
transplant (HCT), studies of caregivers are relatively scarce.
The goal of the current study was to conduct a qualitative
analysis of caregiver QOL after HCT.
Methods: As part of a larger qualitative study examining
patient education regarding post-transplant QOL, caregivers
of patients who had received HCT one to four years previ-
ously were recruited. Participants attended one of four
caregiver-only focus groups. Caregivers were asked to
describe their own QOL after the transplant, how their QOL
differed from what they expected before the transplant, the
most important things they did to improve their QOL, and
how to best educate future HCT caregivers. Verbatim tran-
scripts were coded for a priori and emergent themes using
content analysis.
Results: A total of 15 caregivers participated (67% female,
mean age 57, range 25-65). A major theme was caregivers’
feelings of helplessness and guilt about their inability to ease
patients’ physical and emotional suffering. Caregivers also
emphasized the challenges of caring for the patient while
taking on many of the patient’s previous responsibilities at
home. Many caregivers also struggled with the demands of
raising children and working while caregiving. Another
major theme was ambivalence about leaving the house;
caregivers reported feelings of liberation but also guilt and
worry about leaving the patient at home. Regarding coping,
caregivers reported deriving beneﬁt from religion and spir-
ituality, social support, and activities that helped them
maintain their own sense of identity. Participants described a
desire for more caregiver support programs at the transplant
center as well as informal networks of other HCT caregivers
in their community.
Conclusions: Findings underscore the emotional and phys-
ical challenges of caring for a HCT recipient. Additional ef-
forts are needed to facilitate psychosocial support addressing
caregivers’ unique concerns.
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Background: Hematopoietic stem cell transplantation
(HSCT) has become a standard component of therapy for
several pediatric malignancies. As HSCT improves survival
among those afﬂicted with these malignancies, and sup-
portive care advances diminish the acute toxicities of HSCT,
the risk for late complications in survivors is of increasing
concern. We have recently shown that nearly 80% ofpatients survive beyond 2-years after HSCT. However,
knowledge regarding the burden of morbidity after HSCT
once survivors reach adulthood is sparse. Frequency of
hospitalizations can serve as a proxy measure of morbidity
in this population.
Objectives: To assess the number of hospitalization episodes
in long-term adult survivors of childhood malignancies
treated with HSCT in a tertiary center.
Methods: We used record linkage between the SickKids’
clinical transplant database, the Canadian Province of
Ontario’s pediatric cancer registry (POGONIS) and health
care utilization data housed at the Institute for Clinical
Evaluative Sciences (ICES). The study population included all
adult survivors (age  18 years) of childhood cancer diag-
nosed prior to age 18 years between 1986 and 2005, who had
received cancer therapy that included an allogeneic or
autologous HSCT at SickKids, and who had survived more
than 5 years from transplant. Hospitalizations were captured
from the later of each survivor’s 18th birthday or 5 years after
HSCT until the end of the follow-up period (Dec 2011) or
death.
Results: The cohort consisted of 242 long-term adult survi-
vors who were followed for a mean of 12.3 years. Of these,
148 underwent allogeneic and 86 autologous HSCT. Mean
age at HSCT for the allogeneic group was 11.5 y (SD: 4.7) and
11.0 y (SD: 5.3) for the autologous group. A total of 262
hospitalizations were documented in adults post allogeneic
HSCT, representing a rate of 0.15 hospitalizations per follow-
up year. Univariate analysis revealed that age >10 years at
cancer diagnosis (RR¼3.53, 95% CI: 2.34-5.33), age >10 years
at HSCT (RR¼5.88, 95% CI: 2.89-11.85), and female gender
(RR¼1.70, 95% CI: 1.33-2.18) were associated with an
increased rate of hospitalization. The underlying diagnosis,
ALL vs. AML was not associated with increased rate of hos-
pitalization despite the use of total body irradiation among
ALL patients. A total of 106 hospitalizations were docu-
mented in adults post autologous HSCT, representing a rate
of 0.09 hospitalizations per follow-up year. Age >10 y-o at
time of HSCT (RR¼2.29, 95% CI: 1.29-4.04) and female gender
(RR¼1.70, 95% CI: 1.15-2.52) were associated with increased
rate of hospitalization.
Conclusions: We have identiﬁed risk factors for hospitali-
zation in adults who underwent HSCT during childhood. Age
> 10 years at time of HSCT and female gender were associ-
ated with increased risk for hospitalization. Our future
studies focus on length of stay and the indications for these
hospitalizations.209
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Allogeneic stem cell transplantation (SCT) with both mye-
loablative (MAC) and reduced intensity conditioning (RIC) is
effective therapy in AML andMDS. There is paucity of data on
the long term outcome (beyond 10 years) following RIC due
